Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Ubicación

MS status

Recruitment Status

Fase

Drogas

Inmunoterapia previa permitida

NCT ID

Title key word search

Fecha en que se añadió el juicio

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Fase	Date Added	Ubicación	Prior IO Allowed	CRC-directed	Status	Drogas	Etiquetas
NCT ID NCT05743036	TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer	Fase Fase 1	Date Added 2023-02-24	Ubicación California, United States Kansas, United States Texas, United States Australia Alemania Hungary Italia Polonia España	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas cetuximab, encorafenib, ZN-c3	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05759728	TitleEstudio de CNA3103 (células CAR-T autólogas dirigidas a LGR5) administrado a sujetos con cáncer colorrectal metastásico.	Fase Fase 1	Date Added 2023-03-08	Ubicación Australia	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05714553	TitleNUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours	Fase Phase 1, Phase 2	Date Added 2023-02-06	Ubicación Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Docetaxel, Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab	Etiquetas MSI-H/ MMRd
NCT ID NCT05426005	TitleCadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer	Fase Phase 1, Phase 2	Date Added 2022-06-21	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas Cadonilimab	Etiquetas MSI-H/ MMRd
NCT ID NCT05653882	TitleA Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors	Fase Fase 1	Date Added 2022-12-16	Ubicación California, United States Connecticut, United States Florida, United States Massachusetts, United States Michigan, United States Missouri, United States New Jersey, United States New York, United States North Carolina, United States Tennessee, United States Virginia, United States	Prior IO Allowed Sí	CRC-directed No	Status Reclutamiento	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05464030	TitleAnti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)	Fase Fase 1	Date Added 2022-07-19	Ubicación California, United States Rhode Island, United States Texas, United States Canadá Japón Corea, República de España	Prior IO Allowed Sí	CRC-directed Sí	Status Reclutamiento	Drogas M9140	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05198934	TitleSotorasib y panitumumab frente a la elección del investigador para participantes con sarcoma de rata de Kirsten (KRAS) con mutación p.G12C (CodeBreak 300)	Fase Fase 3	Date Added 2022-01-20	Ubicación Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Francia Alemania Greece Italia Japón Corea, República de Mexico España Taiwán Reino Unido	Prior IO Allowed Sí	CRC-directed Sí	Status Activo, no recluta	Drogas	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05349890	TitlePersonalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)	Fase Fase 1	Date Added 2022-04-27	Ubicación Oregon, United States	Prior IO Allowed Sí	CRC-directed No	Status Activo, no recluta	Drogas CDX-1140, Pembrolizumab, Keytruda	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05350917	TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy	Fase Fase 2	Date Added 2022-04-28	Ubicación	Prior IO Allowed Sí	CRC-directed Sí	Status Aún no se ha contratado	Drogas Tislelizumab	Etiquetas MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05409417	TitleExploratory Study on Combined Conversion Immunotherapy for Liver Metastasis of MSS Type Initial Unresectable Colorectal Cancer Based on Gene Status	Fase Fase 2	Date Added 2022-06-08	Ubicación China	Prior IO Allowed Sí	CRC-directed Sí	Status Unknown status	Drogas Bevacizumab, cetuximab, FOLFOX, Tislelizumab, XELOX	Etiquetas MSS/ MMRp

Showing 131 to 140 of 299 entries